The development of antibody drug conjugates (ADCs) presents a promising alternative to traditional chemotherapy for cancer treatment. By targeting cancer cells specifically, these drugs offer the potential to reduce severe side effects and improve effectiveness. Though widespread adoption may take time, ongoing advancements suggest a future where ADCs play a central role in cancer care.









